Top

Published in:

01-06-2016 | Original Paper

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

Authors: Laura Piccio, Yuetiva Deming, Jorge L. Del-Águila, Laura Ghezzi, David M. Holtzman, Anne M. Fagan, Chiara Fenoglio, Daniela Galimberti, Barbara Borroni, Carlos Cruchaga

Published in: Acta Neuropathologica | Issue 6/2016

Abstract

Low frequency coding variants in TREM2 are associated with increased Alzheimer disease (AD) risk, while loss of functions mutations in the gene lead to an autosomal recessive early-onset dementia, named Nasu-Hakola disease (NHD). TREM2 can be detected as a soluble protein in cerebrospinal fluid (CSF) and plasma, and its CSF levels are elevated in inflammatory CNS diseases. We measured soluble TREM2 (sTREM2) in the CSF of a large AD case–control dataset (n = 180) and 40 TREM2 risk variant carriers to determine whether CSF sTREM2 levels are associated with AD status or mutation status. We also performed genetic studies to identify genetic variants associated with CSF sTREM2 levels. CSF, but not plasma, sTREM2 was highly correlated with CSF total tau and phosphorylated-tau levels (r = 0.35, P < 1×10⁻⁴; r = 0.40, P < 1×10⁻⁴, respectively), but not with CSF Aβ42. AD cases presented higher CSF sTREM2 levels than controls (P = 0.01). Carriers of NHD-associated TREM2 variants presented significantly lower CSF sTREM2 levels, supporting the hypothesis that these mutations lead to reduced protein production/function (R136Q, D87N, Q33X or T66M; P = 1×10⁻³). In contrast, CSF sTREM2 levels were significantly higher in R47H carriers compared to non-carriers (P = 6×10⁻³), suggesting that this variant does not impact protein expression and increases AD risk through a different pathogenic mechanism than NHD variants. In GWAS analyses for CSF sTREM2 levels the most significant signal was located on the MS4A gene locus (P = 5.45 × 10⁻⁰⁷) corresponding to one of the SNPs reported to be associated with AD risk in this locus. Furthermore, SNPs involved in pathways related to virus cellular entry and vesicular trafficking were overrepresented, suggesting that CSF sTREM2 levels could be an informative phenotype for AD.

Available only for authorised users

Atagi Y, Liu CC, Painter MM, Chen XF, Verbeeck C, Zheng H et al (2015) Apolipoprotein E is a ligand for triggering receptor expressed on myeloid cells 2 (TREM2). J Biol Chem 290:26043–26050. doi:10.1074/jbc.M115.679043 CrossRefPubMed

Bailey CC, DeVaux LB, Farzan M (2015) The triggering receptor expressed on myeloid cells 2 binds apolipoprotein E. J Biol Chem 290:26033–26042. doi:10.1074/jbc.M115.677286 CrossRefPubMed

Benitez BA, Cooper B, Pastor P, Jin SC, Lorenzo E, Cervantes S et al (2013) TREM2 is associated with the risk of Alzheimer’s disease in Spanish population. Neurobiol Aging 34(1711):e1715–1717. doi:10.1016/j.neurobiolaging.2012.12.018

Benitez BA, Cruchaga C (2013) TREM2 and neurodegenerative disease. N Engl J Med 369:1567–1568. doi:10.1056/NEJMc1306509#SA4 PubMedPubMedCentral

Benitez BA, Jin SC, Guerreiro R, Graham R, Lord J, Harold D et al (2014) Missense variant in TREML2 protects against Alzheimer’s disease. Neurobiol Aging 35(1510):e1519–1526. doi:10.1016/j.neurobiolaging.2013.12.010

Cady J, Koval ED, Benitez BA, Zaidman C, Jockel-Balsarotti J, Allred P et al (2014) TREM2 variant p. R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71:449–453. doi:10.1001/jamaneurol.2013.6237 CrossRefPubMedPubMedCentral

Cantoni C, Bollman B, Licastro D, Xie M, Mikesell R, Schmidt R et al (2015) TREM2 regulates microglial cell activation in response to demyelination in vivo. Acta Neuropathol 129:429–447. doi:10.1007/s00401-015-1388-1 CrossRefPubMedPubMedCentral

Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015) Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4:7. doi:10.1186/s13742-015-0047-8 CrossRefPubMedPubMedCentral

Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3:445–453. doi:10.1038/nri1106 CrossRefPubMed

10.

Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ et al (2010) YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer’s disease. Biol Psychiatry 68:903–912. doi:10.1016/j.biopsych.2010.08.025 CrossRefPubMedPubMedCentral

11.

Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, Mitra RD et al (2012) Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer’s disease families. PLoS One 7:e31039. doi:10.1371/journal.pone.0031039 CrossRefPubMedPubMedCentral

12.

Cruchaga C, Kauwe JS, Nowotny P, Bales K, Pickering EH, Mayo K et al (2012) Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer’s disease. Hum Mol Genet. doi:10.1093/hmg/dds296

13.

Cruchaga C, Kauwe JS, Harari O, Jin SC, Cai Y, Karch CM et al (2013) GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer’s disease. Neuron. doi:10.1016/j.neuron.2013.02.026

14.

Cuyvers E, Bettens K, Philtjens S, Van Langenhove T, Gijselinck I, van der Zee J et al (2014) Investigating the role of rare heterozygous TREM2 variants in Alzheimer’s disease and frontotemporal dementia. Neurobiol Aging 35(726):e711–729. doi:10.1016/j.neurobiolaging.2013.09.009

15.

Doragna D, Tupler R, Ratti MT, Montalbetti L, Papi L, Sestim R (2003) An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene. J Neurol Neurosurg Psychiatry 74:825–826CrossRef

16.

Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR et al (2006) Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol 59:512–519CrossRefPubMed

17.

Guerreiro R, Bilgic B, Guven G, Bras J, Rohrer J, Lohmann E et al (2013) Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging 34(2890):e2891–2895. doi:10.1016/j.neurobiolaging.2013.06.005

18.

Guerreiro R, Wojtas A, Bras J, Carrasquillo M, Rogaeva E, Majounie E et al (2013) TREM2 variants in Alzheimer’s disease. N Engl J Med 368:117–127. doi:10.1056/NEJMoa1211851 CrossRefPubMedPubMedCentral

19.

Guerreiro RJ, Lohmann E, Bras JM, Gibbs JR, Rohrer JD, Gurunlian N et al (2013) Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol 70:78–84. doi:10.1001/jamaneurol.2013.579 CrossRefPubMedPubMedCentral

20.

Hakola HP (1972) Neuropsychiatric and genetic aspects of a new hereditary disease characterized by progressive dementia and lipomembranous polycystic osteodysplasia. Acta Psychiatr Scand Suppl 232:1–173PubMed

21.

Jin SC, Pastor P, Cooper B, Cervantes S, Benitez BA, Razquin C et al (2012) Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer’s disease Ibero-American cohort. Alzheimers Res Ther 4:34. doi:10.1186/alzrt137 CrossRefPubMedPubMedCentral

22.

Jin SC, Benitez BA, Karch CM, Cooper B, Skorupa T, Carrell D et al (2014) Coding variants in TREM2 increase risk for Alzheimer’s disease. Hum Mol Genet. doi:10.1093/hmg/ddu277

23.

Jin SC, Carrasquillo MM, Benitez BA, Skorupa T, Carrell D, Patel D et al (2015) TREM2 is associated with increased risk for Alzheimer’s disease in African Americans. Mol Neurodegener 10:19. doi:10.1186/s13024-015-0016-9 CrossRefPubMedPubMedCentral

24.

Jonsson T, Stefansson H, Ph DS, Jonsdottir I, Jonsson PV, Snaedal Jet al (2012) Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. doi:10.1056/NEJMoa1211103

25.

Jonsson T, Stefansson K (2013) TREM2 and neurodegenerative disease. N Engl J Med 369:1568–1569. doi:10.1056/NEJMc1306509 PubMed

26.

Kauwe JS, Bailey MH, Ridge PG, Perry R, Wadsworth ME, Hoyt KL et al (2014) Genome-wide association study of CSF levels of 59 Alzheimer’s disease candidate proteins: significant associations with proteins involved in amyloid processing and inflammation. PLoS Genet 10:e1004758. doi:10.1371/journal.pgen.1004758 CrossRefPubMedPubMedCentral

27.

Kleinberger G, Yamanishi Y, Suarez-Calvet M, Czirr E, Lohmann E, Cuyvers E et al (2014) TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med 6:243ra286. doi:10.1126/scitranslmed.3009093

28.

Klunemann HH, Ridha H, Magy L, Wherrett JR, Hemelsoet DM, Keen RW et al (2005) The genetic causes of basal ganglia calcification, dementia, and bone cysts DAP12 and TREM2. Neurology 64:1502–1507. doi:10.1212/01.Wnl.0000160304.00003.Ca CrossRefPubMed

29.

Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C et al (2013) Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer’s disease. Nat Genet. doi:10.1038/ng.2802

30.

Lill CM, Rengmark A, Pihlstrom L, Fogh I, Shatunov A, Sleiman PM et al (2015) The role of TREM2 R47H as a risk factor for Alzheimer’s disease, frontotemporal lobar degeneration, amyotrophic lateral sclerosis, and Parkinson’s disease. Alzheimers Dement. doi:10.1016/j.jalz.2014.12.009

31.

Luis EO, Ortega-Cubero S, Lamet I, Razquin C, Cruchaga C, Benitez BA et al (2014) Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiol Aging. doi:10.1016/j.neurobiolaging.2014.06.007

32.

Ma J, Yu JT, Tan L (2015) MS4A cluster in Alzheimer’s disease. Mol Neurobiol 51:1240–1248. doi:10.1007/s12035-014-8800-z CrossRefPubMed

33.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944CrossRefPubMed

34.

Montalbetti L, Ratti MT, Greco B, Aprile C, Moglia A, Soragna D (2005) Neuropsychological tests and functional nuclear neuroimaging provide evidence of subclinical impairment in Nasu-Hakola disease heterozygotes. Funct Neurol 20:71–75PubMed

35.

Morris JC (1993) The clinical dementia rating (CDR): current version and scoring rules. Neurology 43:2412–2414CrossRefPubMed

36.

Numasawa Y, Yamaura C, Ishihara S, Shintani S, Yamazaki M, Tabunoki H et al (2011) Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur J Neurol 18:1179–1183. doi:10.1111/j.1468-1331.2010.03311.x CrossRefPubMed

37.

Paloneva J, Manninen T, Christman G, Hovanes K, Mandelin J, Adolfsson R et al (2002) Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71:656–662. doi:10.1086/342259 CrossRefPubMedPubMedCentral

38.

Piccio L, Buonsanti C, Mariani M, Cella M, Gilfillan S, Cross AH et al (2007) Blockade of TREM-2 exacerbates experimental autoimmune encephalomyelitis. Eur J Immunol 37:1290–1301. doi:10.1002/eji.200636837 CrossRefPubMed

39.

Piccio L, Buonsanti C, Cella M, Tassi I, Schmidt RE, Fenoglio C et al (2008) Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131:3081–3091. doi:10.1093/brain/awn217 CrossRefPubMedPubMedCentral

40.

Tarawneh R, Lee JM, Ladenson JH, Morris JC, Holtzman DM (2012) CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease. Neurology 78:709–719. doi:10.1212/WNL.0b013e318248e568 CrossRefPubMedPubMedCentral

41.

Vallania FL, Druley TE, Ramos E, Wang J, Borecki I, Province M et al (2010) High-throughput discovery of rare insertions and deletions in large cohorts. Genome Res 20:1711–1718. doi:10.1101/gr.109157.110 CrossRefPubMedPubMedCentral

42.

Wang Y, Cella M, Mallinson K, Ulrich JD, Young KL, Robinette ML et al (2015) TREM2 lipid sensing sustains the microglial response in an Alzheimer’s disease model. Cell 160:1061–1071. doi:10.1016/j.cell.2015.01.049 CrossRefPubMedPubMedCentral

43.

Yang J, Manolio TA, Pasquale LR, Boerwinkle E, Caporaso N, Cunningham JM et al (2011) Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet 43:519–525. doi:10.1038/ng.823 CrossRefPubMedPubMedCentral

44.

Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S et al (2014) An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J Neurosci 34:11929–11947. doi:10.1523/JNEUROSCI.1860-14.2014 CrossRefPubMedPubMedCentral

Title: Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status
Authors: Laura Piccio
Yuetiva Deming
Jorge L. Del-Águila
Laura Ghezzi
David M. Holtzman
Anne M. Fagan
Chiara Fenoglio
Daniela Galimberti
Barbara Borroni
Carlos Cruchaga
Publication date: 01-06-2016
Publisher: Springer Berlin Heidelberg
Published in: Acta Neuropathologica / Issue 6/2016
Print ISSN: 0001-6322
Electronic ISSN: 1432-0533
DOI: https://doi.org/10.1007/s00401-016-1533-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2016

Risk stratification of childhood medulloblastoma in the molecular era: the current consensus

Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors

CSF biomarkers associated with disease heterogeneity in early Parkinson’s disease: the Parkinson’s Progression Markers Initiative study

Genomic characterization of primary central nervous system lymphoma

Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets

Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy